The National Institute of Neurological Disorders and Stroke (NINDS), a civilian agency within the Department of Health and Human Services, awarded an Indefinite Delivery Contract (IDC) with a ceiling value of $37,393,571 to Curia Global Inc., doing business as Amri, a leading global contract development and manufacturing organization (CDMO). The IDC, titled the "Drug Manufacturing and Formulation Program (DMFP)," provides a broad range of pharmaceutical research and development services to NINDS and other NIH institutes, including medicinal chemistry, chemical development, analytical testing, formulation development, and Good Manufacturing Practices (GMP) production.
The task orders issued under this IDC, which do not have any set-aside designations, task Curia with supporting NINDS initiatives across therapeutic areas such as neurology, infectious diseases, and substance abuse. Services to be provided include feasibility studies, clinical trial readiness activities, GMP/clinical trial materials production, exploratory and hit-to-lead chemistry, process chemistry, scale-up synthesis, and stability testing. The task orders have a total ceiling value of over $13 million and performance periods ranging from 2022 to 2030. This IDC award demonstrates Curia's extensive experience supporting the federal government's pharmaceutical research and development needs through prime and subcontract awards.